CurrentBlue KCPolicy POL-PP-272

Diagnosis of Vaginitis

Coverage and medical necessity rules for laboratory and molecular testing used to diagnose causes of vaginitis (BV, VVC, trichomoniasis) for Blue KC members; applies to providers and facilities submitting claims.

Policy Summary

PayerBlue KC

PolicyDiagnosis of Vaginitis

Policy CodePolicy POL-PP-272

Change TypeNo material changes

Effective DateOct 1, 2025

Next Review DateOct 1, 2026

Key ActionReimburse NAAT multi-organism panel testing for symptomatic individuals, limited to one test every 7 days.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1 per 7 daysmaximum frequency for NAAT panel testing

3 causesmost common causes of vaginitis

7 daysminimum treatment window

multiple LOBsapplicable lines of business

Coverage and Medical Necessity Criteria

inv-01: Symptomatic individuals — Allowed testing

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Symptomatic testing allowed: Testing of pH, testing for amines, saline wet mount, KOH (hydrogen peroxide) wet mount, and microscopic examination of vaginal fluids may be reimbursed for individuals with signs and symptoms of vaginitis.

Direct probe and NAAT allowed: Direct probe DNA-based identification of Gardnerella, Trichomonas, and Candida (e.g., BD Affirm VPIII) OR NAAT specific to BV (e.g., Aptima BV; OneSwab BV Panel; SureSwab Advanced BV) OR single/multitarget PCR testing for BV may be reimbursed for symptomatic individuals.

Multi-organism NAAT panels: NAAT panel testing designed to detect more than one type of vaginitis (VVC, BV, and/or trichomoniasis; e.g., BD MAX Vaginal Panel, NuSwab VG, Xpert Xpress MVP) may be reimbursed for symptomatic individuals, limited to no more than one test every seven days.<=1 per 7 days

See Note1 regarding treatment window.

Culture and PCR for Candida: For symptomatic individuals with negative wet-mount findings and normal pH, vaginal cultures for Candida species may be reimbursed. For complicated vulvovaginal candidiasis (VVC), qualitative PCR-based identification of Candida to confirm diagnosis and identify non-albicans species may be reimbursed.

inv-03: Not covered / Experimental

The following tests do not meet coverage criteria due to lack of evidence:

Broad molecular panels for vaginal flora imbalance/infertility: Testing for microorganisms involved in vaginal flora imbalance and/or infertility using molecular-based panel testing may not be reimbursed.

Other unspecified panels: All other tests for vaginitis (for example, broad molecular panels designed to concurrently test for vaginitis and various other sexually transmitted infections) not addressed above may not be reimbursed.

Molecular panel testing that targets microorganisms associated with vaginal flora imbalance and/or infertility is excluded from reimbursement. This exclusion reflects the policy determination that such broad molecular panels do not meet coverage criteria due to insufficient published evidence demonstrating clinical benefit for diagnosis or treatment. Examples include multi-organism panels designed to characterize vaginal microbiota for infertility or dysbiosis without a specific, evidence-supported indication.

Broad molecular-based panels that concurrently test for vaginitis and a range of other sexually transmitted infections are considered not covered. The policy states that any other tests for vaginitis — for example, expansive combination panels not specifically allowed elsewhere in this policy — may not be reimbursed because available published scientific literature does not establish that these tests are required or beneficial for patient care.

Codes and Coding Rules

Covered and referenced laboratory CPT/Proprietary CodesCPT|HCPCS|mixed

81513	Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis.
81514	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), and Lactobacillus species (L. crispatus and L. jensenii), utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis, includes separate detection of Trichomonas vaginalis and/or Candida species when reported.
82120	Amines, vaginal fluid, qualitative.
83986	pH: body fluid, not otherwise specified.
87070	Culture, bacterial; any other source except urine, blood, or stool, aerobic, with isolation and presumptive identification of isolates.
87149	Culture, typing; identification by nucleic acid (DNA or RNA) probe, direct probe technique, per culture or isolate, each organism probed.
87150	Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed.
87210	Smear, primary source with interpretation; wet mount for infectious agents (e.g., saline, India ink, KOH preps).
87480	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique.
87481	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique.

1–10 of 24

1/3

NAAT panel repeat interval (inv-07)

Repeat intervalNo more than one NAAT multi‑organism panel test every 7 days (≤1 per 7 days).

Treatment-window restrictionDo not repeat NAAT panel testing for the three types of vaginitis (VVC, BV, Trichomonas) before a minimum seven‑day treatment window has passed.

Exception when symptoms persistIf symptoms persist despite treatment, individual organism testing may be performed within the seven‑day window.

Provider Responsibilities and Billing Guidance

Billing Rule

NAAT panel testing allowed for symptomatic individuals — reimbursement conditions and limits

For individuals with signs and symptoms of vaginitis, NAAT panel testing (designed to detect more than one type of vaginitis) is reimbursable only for symptomatic individuals and is limited to one test every seven days. The provider must document symptoms and clinical indication on the claim/submission. Coverage is determined by the member's eligibility, benefit limits, date of service, and the Provider Service Agreement.

Allowed example panels: BD MAX Vaginal Panel, NuSwab VG, Xpert Xpress MVP
Limit: No more than one NAAT panel test per member every 7 days

Prior Authorization

PROVIDER ACTIONS — do not repeat NAAT panel testing before 7-day treatment window; guidance if symptoms persist

Do not repeat NAAT panel testing for the same symptomatic episode before the 7-day minimum treatment window has passed. If symptoms persist despite appropriate treatment within that window, providers may perform targeted individual organism testing rather than repeat broad NAAT panel testing; document treatment and ongoing symptoms.

If treatment given (e.g., 7-day course for trichomoniasis), wait until treatment window completes before repeating panel
If symptoms persist within 7 days, perform individual organism tests and document clinical rationale

Documentation Required

PROVIDER ACTIONS — member eligibility, benefit limits, date of service, and Provider Service Agreement influence coverage

Coverage for testing depends on the member's eligibility and benefit limits at the time of service. The date of service and all terms of the Provider Service Agreement apply. For asymptomatic individuals (including asymptomatic pregnant individuals at average or high risk for preterm labor), screening for trichomoniasis and bacterial vaginosis is not reimbursed. Final payment remains subject to claim adjudication and standard coding edits.

Verify member eligibility and benefits prior to testing
Date of service determines applicable coverage rules
Asymptomatic screening for trichomoniasis and BV: not covered

Denial Risk

PROVIDER ACTIONS — tests and broad molecular panels not specifically allowed are not covered / denial risk

Tests and broad molecular panels for vaginal testing that are not specifically addressed as allowed (including molecular panels for vaginal flora imbalance, infertility, or panels that concurrently test for vaginitis and various other STIs) are not covered and may be denied. Providers should order only the tests supported by clinical indications described in this policy and document medical necessity.

Examples not covered: broad molecular panels for vaginal flora imbalance or infertility
Broad panels that include vaginitis plus unrelated STI targets: not covered

Clinical Background

Vaginitis is inflammation of the vagina that commonly presents with discharge, itching, and discomfort. The most frequent causes addressed in this policy are bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomoniasis. BV involves a shift in vaginal flora from Lactobacillus dominance toward Gardnerella and anaerobic organisms; VVC is usually caused by Candida albicans and accounts for approximately one-third of cases; trichomoniasis is infection with Trichomonas vaginalis affecting the squamous epithelium of the urogenital tract.

Definitions and Disease Summaries

Bacterial vaginosis (BV) — definition and brief description (inv-13)

DefinitionBacterial vaginosis (BV) is a shift in vaginal microflora from normally dominant hydrogen peroxide–producing Lactobacillus species to Gardnerella vaginalis and anaerobic commensals.

Clinical presentationBV is one of the most common causes of vaginitis, presenting with vaginal discharge and disruption of normal vaginal flora.

Testing noteNAAT specific to BV and single/multitarget PCR testing for BV may be reimbursed for symptomatic individuals.

Vulvovaginal candidiasis (VVC) — definition and brief description (inv-14)

DefinitionVulvovaginal candidiasis (VVC) is vaginitis usually caused by Candida albicans, though other Candida species can cause infection.

PrevalenceVVC is the second most common cause of vaginitis symptoms and accounts for approximately one‑third of cases.

Testing noteFor symptomatic individuals with negative wet‑mount and normal pH, vaginal cultures and qualitative PCR for Candida (including to identify non‑albicans species in complicated VVC) may be reimbursed.

Trichomoniasis — definition and brief description (inv-15)

DefinitionTrichomoniasis is infection caused by the flagellated protozoan Trichomonas vaginalis, which principally infects the squamous epithelium of the urogenital tract (vagina, urethra, paraurethral glands).

Clinical contextTrichomoniasis is one of the common causes of vaginitis and may be included in multi‑organism NAAT panels reimbursed for symptomatic individuals.

Testing noteNAAT panel testing that includes Trichomonas vaginalis (e.g., BD MAX Vaginal Panel, Xpert Xpress MVP) may be reimbursed for symptomatic individuals, subject to the repeat‑interval restriction.